XVIVO Perfusion

XVIVO Perfusion is the rarest kind of healthcare investment: a company with a technological monopoly in a growing, ethically uncontroversial and regulatorily protected niche — machine preservation of donor organs between retrieval and transplant. Listed in Stockholm and headquartered in Gothenburg, the company has evolved from academic spin-off to global market leader for heart, lung, liver and kidney perfusion machines. Market cap: SEK 9.1B (about $870M).

Operationally, revenue grew +10.2 % to SEK 834M in the last year, driven almost entirely by the US launch of the XVIVO Heart Box (FDA-approved 2024 for DCD heart donors). DCD stands for donation after circulatory death and is the medical game-changer: with the machine in place, hearts from deceased donors — previously unusable — become transplantable again. US transplant authorities estimate this can grow the annual heart donor pool by 30 %.

The problem for the stock: XVIVO is not cheap. Trailing P/E 123.9×, forward P/E 48.8×, EV/EBITDA 63×. Trading at 77.7 % of the 52-week range — no drawdown bargain. Anyone buying here is buying a growth story with medtech optionality, not a value play.

In the current 13F universe none of the BMI-tracked US smart-money managers (Burry, Buffett, Druckenmiller, Ackman) holds an XVIVO position. Structural reason: XVIVO is a Swedish mid-cap without a US ADR — US hedge funds are regulatorily constrained.

Who is actually long: Swedbank Robur and Handelsbanken Fonder as largest institutional holders (~12 % combined). Capital Group holds a 4.8 % position via its Capital International Cayman strategy — the largest international holder. At the insider level: CEO Christoffer Rosenblad holds 1.4 % of the shares — no longer a pre-IPO founder, but strategically CEO since 2020.

Insider activity in the past 12 months: no unusual buys. CFO Kristoffer Nordström sold 8,000 shares at SEK 295 in February 2026 — routine plan, no bear signal. For a stock at 77.7 % of the 52-week range, insider accumulation would be the strongest conviction signal — and it isn't there.

XVIVO Perfusion trades at EV/sales 10.9× — racy, but tolerable given the 73 % gross margin and existing technological barriers. Comparables: TransMedics (TMDX, US) trades at EV/sales 8.7× with 60 % growth; OrganOx (UK) isn't public. Forward P/E 48.8× — justified only if the earnings doubling materializes in 2027. Realistic fair-value range based on 2027 earnings estimate (SEK 6.50 EPS at 35× multiple): SEK 270–320. That matches the current price — no dramatic mispricing, just fair to slightly expensive. Anyone buying should wait below SEK 270 (DCA into correction) rather than going all-in at current levels.

1. Q2 2026 (estimated): FDA expansion of Heart Box indication to pediatric DCD hearts
2. H2 2026: Liver Assist FDA approval decision — expands total addressable market by 50 %
3. Q1 2027: Lung Box Phase 3 trial results — third major asset in the portfolio

XVIVO Perfusion is one of the rare medtech stories where I find the technology operationally convincing — but not the valuation. DCD heart transplantation is real, the TAM is large, and XVIVO has a 5-year lead over TransMedics. Still: forward P/E 48.8 and negative FCF isn't a valuation where I see 5 % position-level risk/reward. My take: maximum 1.5 % portfolio allocation and only as a Swedish mid-cap diversifier. Entry trigger: SEK 240–250 (corresponds to forward P/E 38× and a historical valuation base). Anyone wanting to play the DCD heart trend directly can also buy TransMedics (TMDX) in the US — same trend, liquid ADR.